Haviland Kate's Form 4 filing
Blueprint Medicines Corp (BPMC) · filed Sep 15, 2021
- Accession no.
- 0001179110-21-008782
- Filed
- Sep 15, 2021
- Trade date
- Sep 13, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $99.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Haviland KateCIK 0001663022 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2021 | Common Stock | MOption exerciseAcquired | +1,000 | $36.05 | +$36,050 | 54,948 | Direct | |
| Sep 13, 2021 | Common Stock | SSaleDisposed | −286 | $101.11F2 | −$28,917.46 | 54,662 | Direct | |
| Sep 13, 2021 | Common Stock | SSaleDisposed | −261 | $99.98F3 | −$26,094.78 | 54,401 | Direct | |
| Sep 13, 2021 | Common Stock | SSaleDisposed | −417 | $99.25F4 | −$41,387.25 | 53,984 | Direct | |
| Sep 13, 2021 | Common Stock | SSaleDisposed | −28 | $98.41F5 | −$2,755.48 | 53,956 | Direct | |
| Sep 13, 2021 | Common Stock | SSaleDisposed | −8 | $97.62F6 | −$780.96 | 53,948 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 13, 2021 | Common Stock | MOption exerciseDisposed | −1,000 | $0.00 | $0 | 1,591 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.71 to $101.69 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) in this form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.70 to $100.67 per share.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.70 to $99.67 per share.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.735 to $98.67 per share.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.61 to $97.66 per share.
Referenced by the price of 1 transaction in Table I.